Analysis of risk factors for chronic GVHD
| Factor . | OR . | 95% CI . | P . |
|---|---|---|---|
| RIFNγIntron1-3/3 | 0.56 | 0.18-1.69 | .302 |
| RIFNγIntron1-2/2 | 1.55 | 0.51-4.72 | .445 |
| RIFNγIntron1-2+ | 2.06 | 0.75-5.69 | .162 |
| RIL-6−174GG | 4.25 | 1.49-12.16 | .007 |
| RIL-6−174G+ | 2.81 | 0.70-11.27 | .114 |
| R age (per y) | 1.05 | 0.99-1.11 | .092 |
| R age (> 35 y) | 2.46 | 0.84-7.17 | .099 |
| RCMV+ | 1.52 | 0.58-3.95 | .394 |
| R male | 2.23 | 0.78-6.36 | .132 |
| DIL-6 GG | 3.38 | 0.95-12.10 | .061 |
| DIL-6 G+ | 1.50 | 0.44-5.09 | .516 |
| D age (per y) | 1.04 | 0.99-1.09 | .147 |
| D female | 2.12 | 0.82-5.52 | .121 |
| D female into R male | 2.83 | 0.98-8.19 | .055 |
| DCMV+ | 1.77 | 0.67-4.67 | .250 |
| MTX and/or steroid | 1.60 | 0.57-4.52 | .376 |
| CML | 3.00 | 0.95-9.48 | .061 |
| Factor . | OR . | 95% CI . | P . |
|---|---|---|---|
| RIFNγIntron1-3/3 | 0.56 | 0.18-1.69 | .302 |
| RIFNγIntron1-2/2 | 1.55 | 0.51-4.72 | .445 |
| RIFNγIntron1-2+ | 2.06 | 0.75-5.69 | .162 |
| RIL-6−174GG | 4.25 | 1.49-12.16 | .007 |
| RIL-6−174G+ | 2.81 | 0.70-11.27 | .114 |
| R age (per y) | 1.05 | 0.99-1.11 | .092 |
| R age (> 35 y) | 2.46 | 0.84-7.17 | .099 |
| RCMV+ | 1.52 | 0.58-3.95 | .394 |
| R male | 2.23 | 0.78-6.36 | .132 |
| DIL-6 GG | 3.38 | 0.95-12.10 | .061 |
| DIL-6 G+ | 1.50 | 0.44-5.09 | .516 |
| D age (per y) | 1.04 | 0.99-1.09 | .147 |
| D female | 2.12 | 0.82-5.52 | .121 |
| D female into R male | 2.83 | 0.98-8.19 | .055 |
| DCMV+ | 1.77 | 0.67-4.67 | .250 |
| MTX and/or steroid | 1.60 | 0.57-4.52 | .376 |
| CML | 3.00 | 0.95-9.48 | .061 |
Risk factors for cGVHD by logistic regression. IL-6−174 genotype associates with cGVHD.
For abbreviations, see Table 8.